Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.

Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

Halozyme Therapeutics HALO is scheduled to report fourth-quarter and full-year 2024 results on Feb. 18, after market close.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Subcutaneous Versus Intravenous Amivantamab ... Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: Results From LASER301. J Clin ...

Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP ...

The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity.

according to top-line results from a phase 1b/2a trial. Amycretin (Novo Nordisk) is a once-weekly subcutaneous agent currently under development for the treatment of overweight or obesity and type ...